S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:VBLT

Vascular Biogenics News Headlines

$1.81
+0.02 (+1.12 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.65
Now: $1.81
$1.81
50-Day Range
$1.79
MA: $2.38
$2.91
52-Week Range
$0.90
Now: $1.81
$3.17
Volume437,345 shs
Average Volume1.39 million shs
Market Capitalization$86.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17

Headlines

Vascular Biogenics (NASDAQ VBLT) News Headlines Today

Source:
SourceHeadline
Thinking about buying stock in Super League Gaming, Soligenix, Vascular Biogenics, BioLineRx, or electroCore?Thinking about buying stock in Super League Gaming, Soligenix, Vascular Biogenics, BioLineRx, or electroCore?
prnewswire.com - March 4 at 1:13 PM
Vascular Biogenics (NASDAQ:VBLT) Shares Gap Up to $1.84Vascular Biogenics (NASDAQ:VBLT) Shares Gap Up to $1.84
americanbankingnews.com - March 4 at 12:32 PM
VBL Therapeutics Announces Peer-reviewed Publication of Positive Results of Pre-specified Interim Analysis of OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian CancerVBL Therapeutics Announces Peer-reviewed Publication of Positive Results of Pre-specified Interim Analysis of OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
finance.yahoo.com - March 4 at 8:12 AM
Comparing Vascular Biogenics (NASDAQ:VBLT) and Crinetics Pharmaceuticals (NASDAQ:CRNX)Comparing Vascular Biogenics (NASDAQ:VBLT) and Crinetics Pharmaceuticals (NASDAQ:CRNX)
americanbankingnews.com - March 3 at 10:16 PM
Vascular Biogenics (NASDAQ:VBLT) Trading 6.5% Higher Vascular Biogenics (NASDAQ:VBLT) Trading 6.5% Higher
americanbankingnews.com - March 2 at 7:02 PM
VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma MultiformeVBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme
finance.yahoo.com - March 1 at 8:29 AM
65 Stocks Moving In Tuesdays Mid-Day Session65 Stocks Moving In Tuesday's Mid-Day Session
feeds.benzinga.com - February 23 at 12:24 PM
Vascular Biogenics (NASDAQ:VBLT) Shares Gap Up to $2.23Vascular Biogenics (NASDAQ:VBLT) Shares Gap Up to $2.23
americanbankingnews.com - February 23 at 10:46 AM
48 Stocks Moving in Tuesdays Pre-Market Session48 Stocks Moving in Tuesday's Pre-Market Session
msn.com - February 23 at 8:06 AM
Vascular Biogenics (NASDAQ:VBLT) Trading Down 12.5%Vascular Biogenics (NASDAQ:VBLT) Trading Down 12.5%
americanbankingnews.com - February 22 at 10:20 PM
Vascular Biogenics Ovarian Cancer Gene Therapy Study To Continue, Recommends An Independent CommitteeVascular Biogenics' Ovarian Cancer Gene Therapy Study To Continue, Recommends An Independent Committee
finance.yahoo.com - February 22 at 8:04 PM
VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian CancerVBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
finance.yahoo.com - February 22 at 8:36 AM
Vascular Biogenics (NASDAQ:VBLT) Trading 12.6% Higher Vascular Biogenics (NASDAQ:VBLT) Trading 12.6% Higher
americanbankingnews.com - February 10 at 7:16 PM
Heres Why Were Watching Vascular Biogenics (NASDAQ:VBLT) Cash Burn SituationHere's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation
finance.yahoo.com - January 19 at 3:33 PM
VBL Therapeutics Announces First Patient in Europe in the OVAL TrialVBL Therapeutics Announces First Patient in Europe in the OVAL Trial
finance.yahoo.com - December 29 at 8:23 AM
VBL Therapeutics Announces Insider BuyingVBL Therapeutics Announces Insider Buying
finance.yahoo.com - December 7 at 7:52 AM
Vascular Biogenics Ltd. (NASDAQ:VBLT) Analysts Just Slashed Next Years Revenue Estimates By 16%Vascular Biogenics Ltd. (NASDAQ:VBLT) Analysts Just Slashed Next Year's Revenue Estimates By 16%
finance.yahoo.com - November 18 at 9:07 AM
Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue EstimatesVascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 16 at 1:01 PM
How Much Is Vascular Biogenics Ltd. (NASDAQ:VBLT) Paying Its CEO?How Much Is Vascular Biogenics Ltd. (NASDAQ:VBLT) Paying Its CEO?
finance.yahoo.com - November 16 at 1:01 PM
Vascular Biogenics: Q3 Earnings InsightsVascular Biogenics: Q3 Earnings Insights
benzinga.com - November 16 at 8:00 AM
Earnings Outlook For Vascular BiogenicsEarnings Outlook For Vascular Biogenics
benzinga.com - November 13 at 12:32 PM
VBL Therapeutics to Present at the H.C. Wainwright 6th Annual Israel ConferenceVBL Therapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference
finance.yahoo.com - November 5 at 7:36 AM
VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16
finance.yahoo.com - November 2 at 7:07 AM
VBL Therapeutics Announces Additional New European Patent in the MOSPD2 Platform Technology, This Time for Treatment of CancerVBL Therapeutics Announces Additional New European Patent in the MOSPD2 Platform Technology, This Time for Treatment of Cancer
finance.yahoo.com - October 23 at 8:42 PM
VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitVBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
finance.yahoo.com - September 21 at 7:23 PM
Who Has Been Buying Vascular Biogenics Ltd. (NASDAQ:VBLT) Shares?Who Has Been Buying Vascular Biogenics Ltd. (NASDAQ:VBLT) Shares?
finance.yahoo.com - September 17 at 6:11 PM
VBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment ConferenceVBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment Conference
finance.yahoo.com - September 15 at 8:38 AM
Thinking about buying stock in Avinger, Vascular Biogenics, Intra-Cellular Therapies, Agenus, or Co-Diagnostics?Thinking about buying stock in Avinger, Vascular Biogenics, Intra-Cellular Therapies, Agenus, or Co-Diagnostics?
marketwatch.com - September 13 at 8:25 PM
VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple Sclerosis at the MS Virtual 2020 MeetingVBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple Sclerosis at the MS Virtual 2020 Meeting
finance.yahoo.com - September 11 at 12:27 PM
VBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal CancerVBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal Cancer
finance.yahoo.com - September 10 at 10:16 AM
VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601
finance.yahoo.com - September 8 at 9:16 AM
Vascular Biogenics Ltd (VBLT) CEO Dror Harats on Q2 2020 Results - Earnings Call TranscriptVascular Biogenics Ltd (VBLT) CEO Dror Harats on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 13 at 1:41 PM
Vascular Biogenics: Q2 Earnings InsightsVascular Biogenics: Q2 Earnings Insights
benzinga.com - August 13 at 8:40 AM
VBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate UpdateVBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - August 13 at 8:40 AM
VBL Therapeutics late-stage study of lead drug in ovarian cancer to continueVBL Therapeutics late-stage study of lead drug in ovarian cancer to continue
seekingalpha.com - August 12 at 12:36 PM
VBL Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review Looking at OS - the Primary Endpoint of the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian CancerVBL Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review Looking at OS - the Primary Endpoint of the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer
finance.yahoo.com - August 12 at 12:36 PM
Earnings Preview: Vascular Biogenics (VBLT) Q2 Earnings Expected to DeclineEarnings Preview: Vascular Biogenics (VBLT) Q2 Earnings Expected to Decline
finance.yahoo.com - August 6 at 6:07 PM
VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13
finance.yahoo.com - August 3 at 8:29 AM
Growth Investors: Industry Analysts Just Upgraded Their Vascular Biogenics Ltd. (NASDAQ:VBLT) Revenue Forecasts By 24%Growth Investors: Industry Analysts Just Upgraded Their Vascular Biogenics Ltd. (NASDAQ:VBLT) Revenue Forecasts By 24%
finance.yahoo.com - June 25 at 10:12 AM
VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual MeetingVBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting
finance.yahoo.com - June 22 at 10:13 AM
VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 CongressVBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress
finance.yahoo.com - June 4 at 11:03 AM
BRIEF-VBL Presents Positive Interim Data From Pivotal Study In Ovarian CancerBRIEF-VBL Presents Positive Interim Data From Pivotal Study In Ovarian Cancer
www.reuters.com - June 1 at 10:39 PM
VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response RateVBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response Rate
finance.yahoo.com - June 1 at 7:37 AM
Earnings Update: Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Are Boosting Their EstimatesEarnings Update: Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Are Boosting Their Estimates
finance.yahoo.com - May 18 at 2:10 PM
VBL Therapeutics to Present New Data on Its MOSPD2 Bispecific Antibody Program for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual MeetingVBL Therapeutics to Present New Data on Its MOSPD2 Bispecific Antibody Program for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting
finance.yahoo.com - May 18 at 9:09 AM
This Just In: Analysts Are Boosting Their Vascular Biogenics Ltd. (NASDAQ:VBLT) Outlook for This YearThis Just In: Analysts Are Boosting Their Vascular Biogenics Ltd. (NASDAQ:VBLT) Outlook for This Year
finance.yahoo.com - May 15 at 3:42 PM
Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q1 2020 Results - Earnings Call TranscriptVascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 5:45 PM
Vascular Biogenics (VBLT) Reports Q1 Loss, Tops Revenue EstimatesVascular Biogenics (VBLT) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 14 at 12:45 PM
Recap: Vascular Biogenics Q1 EarningsRecap: Vascular Biogenics Q1 Earnings
finance.yahoo.com - May 14 at 12:45 PM
VBL Therapeutics Announces First Quarter 2020 Financial Results and Provides Corporate UpdateVBL Therapeutics Announces First Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - May 14 at 7:43 AM
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.